Ask AI
ProCE Banner Activity

Case Challenges: Expert Insights on CAR T-Cell Therapy and Adverse Event Management in B-Cell Lymphoma

Clinical Thought

Read this commentary for expert thoughts on CAR T-cell therapy treatment approaches for B-cell lymphoma patient cases presented at an ASH 2025 satellite symposium.

Released: February 25, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb and Kite Pharma, Inc.

Bristol Myers Squibb

Kite Pharma, Inc.

Target Audience

This activity aims to improve learners’ knowledge, competence, and performance in application of current and emerging CAR T-cell therapy for patients with various forms of relapsed or refractory B-cell non-Hodgkin lymphoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Demonstrate the ability to select appropriate candidates for CAR T-cell therapy in DLBCL, FL, MCL, and CLL/SLL, applying current evidence and FDA-approved indications

  • Construct comprehensive care plans for patients undergoing CAR T-cell therapy, including referral, pre-treatment preparations, and post-treatment monitoring

  • Formulate evidence-based management strategies for CAR T-cell therapy-related adverse events, including cytokine release syndrome and neurotoxicity

Disclosure

Primary Author

Jeremy S. Abramson, MD, MMSc: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Caribou, Foresight Diagnostics, Genentech, Johnson & Johnson, Lilly, Miltenyi, Novartis, Roche; researcher: Allogene, Bristol Myers Squibb, Cellectis, Genentech, Merck, Mustang Bio, Regeneron, Seagen, Takeda.

Stephen M. Ansell, MD, PhD: researcher: ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Enterome, Pfizer, Regeneron, Step Pharma, Takeda. 

David G. Maloney, MD, PhD: consultant/advisor/speaker: A2 Biotherapeutics, Artiva Biotherapeutics, Bristol Myers Squibb, Caribou, Genentech, Gilead, Novartis, Umoja Biopharma.